Article

No impact of anti-inflammatory diet on health-related quality of life in RA


 

Key clinical point: The anti-inflammatory diet did not enhance health-related quality of life in patients with rheumatoid arthritis (RA) compared with a control diet. However, physical functioning improved significantly, particularly in patients who did not alter antirheumatic medication.

Major finding: The Health Assessment Questionnaire was not significantly different between the intervention and control diet periods ( P = .503); however, the physical functioning improved significantly during intervention diet vs. control diet period (mean, 5.791; 95% CI, 1.576-10.005), particularly in patients without pharmacological treatment changes (mean, 7.898; P = .036).

Study details: Findings are from the ADIRA trial , a controlled crossover trial including 50 patients with RA who were randomly assigned to either an intervention diet including foods with suggested anti-inflammatory properties and promising effects on RA symptoms (n=24) or control diet (usual Swedish diet; n=26) for 10 weeks before switching to the other diet.

Disclosures: This study received grants from the Swedish government, Swedish Research Council for Health, Working Life and Welfare, and others. No conflict of interests was reported.

Source: Turesson Wadell A et al. PLoS One. 2021 Oct 14. doi: 10.1371/journal.pone.0258716 .

Recommended Reading

Long-term glucocorticoids in RA linked to increased cardiovascular risk
MDedge Rheumatology
Low-dose rituximab may keep RA disease activity low in responders
MDedge Rheumatology
No risk of increased flare after 2 doses of COVID-19 vaccination in RA
MDedge Rheumatology
RA: bDMARD monotherapy may accelerate radiographic progression of preexisting distal hand osteoarthritis
MDedge Rheumatology
Baricitinib demonstrates consistent long-term safety profile in RA
MDedge Rheumatology
T-helper cell derangements tied to atrial fibrillation in RA
MDedge Rheumatology
Certolizumab seems effective as monotherapy in RA patients with failure to csDMARDs
MDedge Rheumatology
Obesity, depression, anxiety, and illness beliefs influence remission, pain, and fatigue in RA
MDedge Rheumatology
Similar long-term safety/tolerability of filgotinib 100 mg and 200 mg in moderate-to-severe RA
MDedge Rheumatology
Sinusitis and upper respiratory tract diseases may increase the risk for rheumatoid arthritis
MDedge Rheumatology